Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tamaristin in preparation of medicine for preventing or treating ischemic encephalopathy

A technology for ischemic encephalopathy and ischemic stroke, which is applied in the field of preparation of drugs for the prevention or treatment of ischemic encephalopathy, and can solve the problems that the preventive or therapeutic effect of tamarind has not yet been seen, and achieve good therapeutic effect, Improvement effect on cognitive impairment

Pending Publication Date: 2022-07-22
NORTHEASTERN UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, so far, there has been no relevant report on the preventive or therapeutic effect of tamarind on ischemic encephalopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tamaristin in preparation of medicine for preventing or treating ischemic encephalopathy
  • Application of tamaristin in preparation of medicine for preventing or treating ischemic encephalopathy
  • Application of tamaristin in preparation of medicine for preventing or treating ischemic encephalopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Improvement effect of tamarind on acute ischemic stroke

[0045] 1. Experimental grouping and scheme

[0046] Unless otherwise specified, the embodiment of the present invention adopts the following modeling and grouping methods:

[0047] Healthy SPF grade male Sprague-Dawley (SD) rats purchased from Liaoning Changsheng Biotechnology Co., Ltd. were randomly divided into 6 groups, namely control group, model group, model group + low-dose tamarind group (5mg / kg) , model group + tamarind medium dose group (10mg / kg), model group + tamarind high dose group (20mg / kg), model group + positive drug quercetin group (20mg / kg). Tamarind or quercetin was given by gavage 3 days before the operation, and the rats in the control group were given an equal volume of 0.5% sodium carboxymethyl cellulose suspension once a day. After SD rats were anesthetized, the left common carotid artery, external carotid artery and internal carotid artery of the rats were exposed. A smooth ...

Embodiment 2

[0077] Example 2: Improvement effect of tamarind on cognitive impairment in the recovery period of ischemic stroke

[0078] 1. Experimental grouping and scheme

[0079] The grouping of rats and the MCAO / R surgical procedure were the same as those in Example 1. After 1 h of ischemia, the suture was pulled out for blood reperfusion. Drugs were given by gavage 3 days before surgery, and the control group was given an equal volume of 0.5% sodium carboxymethyl cellulose suspension by gavage, once a day until the end of the experiment. After 14 days, Y-maze test, dark avoidance test, and Morris water maze test were performed to observe the learning, memory and cognitive ability of rats to evaluate the improvement effect of tamarind on cognitive impairment in the recovery period of ischemic stroke.

[0080] Data were analyzed using SPSS 22.0 software (SPSS Inc., Chicago, USA), and data are presented as mean ± SEM. One-way ANOVA for Y-maze, dark avoidance experiment, Morris water m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of natural medicines, and particularly relates to application of tamaristin in preparation of medicines for preventing or treating ischemic encephalopathy. Specifically, the invention relates to application of tamarix flavin in preparation of drugs for preventing or treating cerebral arterial thrombosis. Pharmacological experiments show that tamarix flavin has an obvious treatment effect on dyskinesia and neurological impairment of focal ischemic stroke model rats caused by middle artery ischemia reperfusion; the compound also has a remarkable improvement effect on learning and memory cognitive impairment of the model rat, so that the compound can be used for preparing medicines for preventing or treating related ischemic encephalopathy.

Description

technical field [0001] The invention belongs to the field of natural medicines, in particular to the application of tamarind in the preparation of medicines for preventing or treating ischemic encephalopathy. Background technique [0002] Ischemic encephalopathy is a common senile disease that is caused by insufficient blood supply to the brain due to stenosis or occlusion of the arteries supplying blood to the brain, resulting in brain tissue necrosis. Common clinical symptoms include unconsciousness, speech difficulties, facial paralysis, limb numbness, weakness, perceptual disturbance, dizziness, and ataxia. The incidence of ischemic encephalopathy is high. At present, there are about 1.6 million new ischemic encephalopathy patients in my country every year. In addition, the death and disability rates of such diseases are also high. Studies have shown that 75% of patients will die or be left with varying degrees of disability. This type of disease has the characteristi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K45/06A61K31/365A61K31/4152A61K31/4422A61P9/10A61P25/00A61P25/28
CPCA61K31/352A61K45/06A61K31/365A61K31/4152A61K31/4422A61K9/0053A61K9/0019A61P9/10A61P25/00A61P25/28A61K2300/00
Inventor 侯悦李宁何大阔杨艳秋
Owner NORTHEASTERN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com